New developments in scleroderma interstitial lung disease

Current Opinion in Rheumatology

Volumn 17, Issue 6, 2005, Pages 737-745

  Highland, Kristin B ^a   Silver, Richard M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Interstitial lung disease; Pulmonary fibrosis; Scleroderma; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; BETA THROMBOGLOBULIN; BOSENTAN; CELL ADHESION MOLECULE; CHEMOKINE; CURCUMIN; CYCLOPHOSPHAMIDE; CYTOKINE; DNA TOPOISOMERASE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FIBROBLAST ANTIBODY; GLYCOPROTEIN; GLYCOPROTEIN KL 6; IMMUNOSUPPRESSIVE AGENT; MATRIX METALLOPROTEINASE 3 ANTIBODY; P SELECTIN GLYCOPROTEIN LIGAND 1; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PREDNISONE; RHEUMATOID FACTOR; STROMELYSIN; SURFACTANT PROTEIN D; THROMBIN; THROMBOCYTE FACTOR 4; TOPOISOMERASE I AUTOANTIBODY; UNCLASSIFIED DRUG;

CAPILLAROSCOPY; CELLULAR DISTRIBUTION; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE MARKER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; MEDICAL INFORMATION; META ANALYSIS; MICROANGIOPATHY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

BIOPSY; BRONCHOALVEOLAR LAVAGE; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 27544457273     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000181534.67685.5a     Document Type: Review

References (60)

1. Beon M, Harley RA, Wessels A, et al. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol 2005; 22: 733-742. This is a study of postmortem SSc lung tissue demonstrating induction of a large number of smooth muscle α-actin-positive myofibroblasts in the interstitium and formation of alveolar capillaries accompanied by an increase in the number of microvascular endothelial cells. Such findings occur in early active stages of SSc lung fibrosis, but decline with end-stage fibrosis.
2. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996; 22:709-735.
3. Sato S, Hamaguchi Y, Hasegawa M, Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford) 2001; 40:1135-1140.
4. Hénault J, Tremblay M, Clément I, et al. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004; 50:3265-3274. This is the first study to demonstrate the direct binding of anti-topoisomerase I autoantibodies from SSc patients to the fibroblast cell surface.
5. Nishijima C, Hayakawa I, Matsushita T, et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004; 138:357-363.
6. Mimura Y, Ihn H, Jinnin M, et al. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis. Br J Dermatol 2004; 803-808.
7. Scala E, Pallotta S, Frezzolini A, et al. Cytokine and chemokine levels in systemic sclerosis; relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138:540-546. This study of 54 consecutive patients with SSc identifies quantitative and qualitative changes in cytokine and chemokine production compared to healthy subjects. Cytokine and chemokine profiles variably correlated with cutaneous and internal organ involvement. There was a significant direct correlation between pulmonary fibrosis and serum IL-6 and IL-10 from T cell lines, and an inverse relationship to MCP-1 from T cell lines.
8. Fujii H, Hasegawa M, Takehara K, et al. Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol 2002; 130:548-556.
9. Widom RL. Regulation of matrix biosynthesis and degradation in systemic sclerosis. Curr Opin Rheumatol 2000; 12:534-539.
10. Sakkas LI, Xu B, Artett CM, et al. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002; 168:3649-3659.
11. Hamilton RF, Parsley E, Holian A. Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes. Am J Physiol Lung Cell Mol Physiol 2004; 286:L1202-L1209.
12. Meloni F, Caporali R, Marone Bianco A, et al. Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: comparison with usual interstitial pneumonia. Ann Rheum Dis 2004; 63:892-894. This study suggests that the cytokine profile of BALF in SSc-ILD may reflect a more favorable balance between fibrotic (MCP-1) and antifibrotic (IL-12) or anti-inflammatory (IL-10) factors as compared to patients with DIP. These data should be interpreted with caution given the small numbers of patients and the wide range in BALF cytokine concentrations.
13. 3CRI compared to normal controls. Furthermore soluble FKN levels were significantly associated with the involvement and severity of pulmonary fibrosis.
14. Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001; 276:45184-45192.
15. Bogatkevich GS, Tourkina E, Abrams CS, et al. Contractile activity and smooth muscle-α actin organization in thrombin-induced human lung myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2003; 285:L334-L343.
16. Bogatkevich GS, Gustio E, Oates JC, et al. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2004; 288:L190-L201. This article provides compelling evidence that thrombin stimulates unrestricted proliferation and cell survival and initiates tissue repair in scleroderma lung fibroblasts, which may have significant relevance to the pathogenesis of lung fibrosis.
17. Abraham DJ, Vancheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997; 151:831-841.
18. Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phophoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15:2707-2719. These authors demonstrate that ET-1 induced the myofibroblast phenotype and subsequent contraction. The authors also demonstrated that patients with SSc have enhanced ET-1 expression and binding. These studies suggest that ET-1 blockade may be a useful strategy for treating SSc-ILD and, indeed, a clinical trial of the dual endothelin receptor antagonist, bosentan, is currently underway.
19. Kowal-Bielecka O, Kowal K, Lewszuk A, et al. B Thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 2005; 64:484-486. In this study, increased concentrations of BTG and PF4 were found in BALF exclusively in patients with early SSc-ILD suggesting a role for microvascular injury in the development of SSc-ILD.
20. Gruschwitz MS, Hornstein OP, von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995; 38:184-189.
21. Denton CP, Bickerstaff MCM, Shiwen X, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995; 34:1048-1054.
22. Patel KD, Moore KL, Nollert MU, McEver RP. Neutrophils use both shared and distinct mechanisms to adhere to selectins under static and flow conditions. J Clin Invest 1995; 96:1887-1896.
23. Asa D, Raycroft L, Ma L, et al. The P-selectin glycoprotein ligand functions as a common human leukocyte ligand for P- and E-selectins. J Biol Chem 1995; 270:11662-11670.
24. Yanaba K, Takehara K, Sato S. Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis. Ann Rheum Dis 2004; 63:583-587.
25. + T cell numbers decrease in systemic sclerosis. Clin Exp Immunol 2005; 139:551-557.
26. Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232: 560-567. This is the largest study to date describing the CT characteristics of patients with SSc-ILD. This study found that the CT features of SSc-ILD closely resemble those in patients with NSIP and are in keeping with recent observations that NSIP is the most prevalent histopathologic pattern at open lung biopsy.
27. Fujita J, Yoshinouchi T, Ohtuski Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001; 60:281-283.
28. Kim DS, Yoo B, Lee JS, et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vase Diffuse Lung Dis 2002; 19:121-127.
29. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581-1586.
30. Silver RM, Miller KS, Kinsella MB, et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88:470-476.
31. Remy Jardin M, Remy J, Wallaert B, et al. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993; 188:499-506.
32. Clements PJ, Goldin JG, Kleerup EC, et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004; 50: 1909-1917. This study shows that agreement between HRCT findings of ground-glass opacification and BAL positivity was dependent upon which lobe was examined: agreement was excellent for the middle lobe or lingula but poor for the lower lobes.
33. Maricq HR, LeRoy EC, D'Angelo WA, et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980; 23:183-189.
34. Bredemeier M, Xavier RM, Capobianco G, et al. Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol 2004; 31:286-294. This study shows that abnormalities on nailfold capillaroscopy may be early findings in SSc-ILD, and nailfold capillaroscopy is a highly sensitive test in predicting patients with ground-glass opacity on HRCT with less than 5 years of disease duration.
35. Silver RM, Metcalf JF, Stanley JH, LeRoy EC. Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum 1984; 27:1254-1262.
36. Yamane K, Ihn H, Kubo M, et al. Serum concentrations of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 2000; 7:930-034.
37. Sato S, Nagaoka T, Hasegawa M, et al. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 2000; 200:196-201.
38. Vesey R, Vargova V, Ravelli A, et al. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. J Rheumatol 2004; 31:795-800. This study of 12 children with juvenile SSc demonstrates that measurement of serum KL-6 may be a useful noninvasive marker of pulmonary fibrosis. KL-6 was inversely correlated with vital capacity and diffusion capacity. Analysis of individual patients showed that serum concentrations of KL-6 were correlated with ILD severity and its response to treatment.
39. Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000; 12:258-263.
40. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31:1112-1120. Serum levels of surfactant protein-D (SP-D) and KL-6 were measured in 42 Japanese SSc patients, including a retrospective longitudinal study of 83 samples from 6 patients. SP-D was a more sensitive marker for ILD than KL-6, and KL-6 showed higher specificity than SP-D. SP-D levels were more responsive to change and tended to reflect ILD activity more so than KL-6.
41. Asano Y, Ihn H, Yamane K, et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001; 44:1363-1369.
42. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-993.
43. Hesselstrand R, Ekman R, Eskilsson J, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatol 2005; 44: 366-371. This is the largest study to date of consecutive echocardiograms in early SSc. This study shows that increased pulmonary pressures are common and progressive in SSc. The presence of ILD is an independent risk factor for an increased tricuspid valve gradient.
44. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088-1093.
45. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947-954.
46. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37:729-735.
47. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20:834-844.
48. Steen VD, Lanz JK Jr, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. Arthritis Rheum 1994; 37:1290-1296.
49. Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect of high resolution computed tomography scan and lung function. J Rheumatol 2002; 29:2371-2378.
50. Airo P, Danieli E, Parrinello G, et al. Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004; 22:573-578.
51. Apras S, Ertenli I, Ozbalkan Z, et al. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003; 48:2256-2261.
52. Davas EM, Peppas C, Maragou M, et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18:455-461.
53. Pakas I, Ioannidis JP, Malagari K, et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29:298-304.
54. Khanna D, Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the scleroderma lung study. Arthritis Rheum 2005; 52:592-600. SSc-ILD patients with greater severity of dyspnea have lower health-related quality of life, greater functional disability, poorer patient global assessment of their disease and greater decreases in physiologic measures of lung function (FVC and DLCO). In this report from the SLS the patient self-assessed measures of disease were noted to be stronger correlates of dyspnea than were physiologic measures.
55. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004; 23:306-309. This is the first case series of patients with SSc-associated ILD treated with azathioprine. The results suggest that azathioprine may have a role in stabilizing lung function and improving symptoms in SSc, although this needs confirmation by a randomized trial.
56. Tourkina E, Gooz P, Oates J, et al. Curcumin-induced apoptosis in scleroderma lung fibroblasts. Am J Respir Cell Mol Biol 2004; 31:28-35.
57. Vemkatesan N, Punithavathi V, Chandrakasan G. Curcumin protects bleomycin induced lung injury in rats. Life Sci 1997; 61:PL51-PL58.
58. Venkatesan N. Chandrakasan. Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory oxidant. Mol Cell Biochem 1995; 142:79-87.
59. Thresiamma KC, George JL, Kuttan R. Protective effect of curcumin, ellagic acid and bixin on radiation induced toxicity. Journal of Experimental & Clinical Cancer Research 1996; 34:845-847.
60. Ioannidis JPA, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118:2-10. This is the largest case series to date that looks at predictors of mortality in SSc. The authors found that SSc confers a high mortality risk, but there is considerable heterogeneity across settings. Internal organ involvement and anti-topoisomerase I antibodies are important determinants of mortality.